This Speaker Series presented by Professor Emanuel Della Torre’s (Vita-Salute San Raffaele University, Italy) reviews diagnostic pathways, key clinical trials, and the long-term safety profile of siltuximab, the most studied and approved option for idiopathic multicentric Castleman disease.
Please login below to download this issue (PDF)